Therapeutic management of advanced Adrenocortical carcinoma: What do we know in 2011?

被引：33
作者：
Baudin E. [1 ,7 ]
Leboulleux S. [1 ,9 ]
Al Ghuzlan A. [2 ,10 ]
Chougnet C. [1 ,11 ]
Young J. [3 ,12 ]
Deandreis D. [1 ,13 ]
Dumont F. [4 ,14 ]
Dechamps F. [5 ,15 ]
Caramella C. [5 ,15 ]
Chanson P. [3 ,18 ]
Lanoy E. [6 ,17 ]
Borget I. [6 ,16 ]
Schlumberger M. [1 ,19 ]
机构：
[1] Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, Univ. Paris-Sud, Villejuif
[2] Department of Pathology, Institut Gustave Roussy, Villejuif
[3] Department of Endocrinology, Univ. Paris-Sud, Faculté de Médecine Paris-Sud, UMR-S693, APHP Hôpitaux Universitaires Paris-Sud, Institut National de la Sante et de la Recherche Medicale U693
[4] Department of Oncologic Surgery, Institut Gustave Roussy, Univ. Paris-Sud
[5] Department of Radiology, Institut Gustave Roussy, Villejuif
[6] Department of Epidemiology, Institut Gustave Roussy, Villejuif
[7] Department of Endocrine Oncology, Univ. Paris-Sud, Faculté de Médecine Paris-Sud
[8] Institut National de la Sante et de la Recherche Med. U693
[9] Department of Endocrine Oncology, Univ. Paris-Sud, Faculté de Médecine Paris-Sud, APHP Hôpitaux Universitaires Paris-Sud
[10] Department of Pathology, Univ. Paris-Sud, Faculté de Médecine Paris-Sud, APHP Hôpitaux Universitaires Paris-Sud
[11] Department of Endocrine Oncology, Univ. Paris-Sud, Faculté de Médecine Paris-Sud, APHP Hôpitaux Universitaires Paris-Sud
[12] Department of Endocrinology, Institut Gustave Roussy, Le Kremlin-Bicêtre
[13] Department of Nuclear Medicine, Univ. Paris-Sud, Faculté de Médecine Paris-Sud, APHP Hôpitaux Universitaires Paris-Sud
[14] Department of Surgery, Univ. Paris-Sud, Faculté de Médecine Paris-Sud, APHP Hôpitaux Universitaires Paris-Sud
[15] Department of Radiology, Univ. Paris-Sud, Faculté de Médecine Paris-Sud, APHP Hôpitaux Universitaires Paris-Sud
[16] Department of Epidemiology, Univ. Paris-Sud, Faculté de Médecine Paris-Sud, APHP Hôpitaux Universitaires Paris-Sud
[17] Department of Epidemiology, Univ. Paris-Sud, Faculté de Médecine Paris-Sud, APHP Hôpitaux Universitaires Paris-Sud
[18] Department of Endocrinology, Le Kremlin Bicêtre, Villejuif
[19] Department of Endocrinology, Univ. Paris-Sud, Faculté de Médecine Paris-Sud, APHP Hôpitaux Universitaires Paris-Sud
来源：
Hormones and Cancer | 2011年 / 2卷 / 6期
关键词：
Adrenocortical carcinoma; Predictive markers surrogates; Prognosis; Treatment;
D O I：
10.1007/s12672-011-0094-2
中图分类号：
学科分类号：
摘要：
The prognosis of advanced adrenocortical carcinoma (ACC) is dismal but heterogeneous. In 2011, mitotane is the only drug approved in Europe and US for the treatment of advanced ACC. Mitotane exerts both antisecretory and antiproliferative effects, which are delayed over time, and requires careful biological and morphological evaluations coupled with mitotane plasma measurement monitoring. In the absence of demonstration of any superior activity of combined polychemotherapy, the least toxic regimen should be considered in routine care. Locoregional therapies, including surgery of the primary tumor and metastases, should be considered part of the therapeutic arsenal. A prolonged survival can be observed in the case of tumor objective response and/or high plasma mitotane levels. New protocols are urgently needed, coupled with ancillary studies dedicated to progress in the findings of predictors or surrogates. International networks and comprehensive databases gathering clinical and biological data constitute the prerequisites for progress. © 2011 Springer Science+Business Media, LLC.
引用
收藏
页码：363 / 371
页数：8
相关论文
共 55 条
  • [1] Fassnacht M., Johanssen S., Quinkler M., Bucsky P., Willenberg H.S., Beuschlein F., Terzolo M., Mueller H.H., Hahner S., Allolio B., 2009 Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification, Cancer, 115, pp. 243-250, (2009)
  • [2] Icard P., Goudet P., Charpenay C., Andreassian B., Carnaille B., Chapuis Y., Cougard P., Henry J.F., Proye C., Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group, World J Surg, 25, pp. 891-897, (2001)
  • [3] Lughezzani G., Sun M., Perrot P., Jeldres C., Alasker A., Isbarn H., Budaus L., Shariat S.F., Guazzoni G., Montorsi F., Karakiewicz P.I., The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the International Union Against Cancer-staging system, Eur J Cancer, 46, pp. 713-719, (2010)
  • [4] Assie G., Antoni G., Tissier F., Caillou B., Abiven G., Gicquel C., Leboulleux S., Travagli J.P., Dromain C., Bertagna X., Bertherat J., Schlumberger M., Baudin E., Prognostic parameters of metastatic adrenocortical carcinoma, J Clin Endocrinol Metab, 92, pp. 148-154, (2007)
  • [5] Decker R.A., Elson P., Hogan T.F., Citrin D.L., Westring D.W., Banerjee T.K., Gilchrist K.W., Horton J., Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma, Surgery, 110, pp. 1006-1013, (1991)
  • [6] Bukowski R.M., Wolfe M., Levine H.S., Crawford D.E., Stephens R.L., Gaynor E., Harker W.G., Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study, J Clin Oncol, 11, pp. 161-165, (1993)
  • [7] Abraham J., Bakke S., Rutt A., Meadows B., Merino M., Alexander R., Schrump D., Bartlett D., Choyke P., Robey R., Hung E., Steinberg S.M., Bates S., Fojo T., A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist, Cancer, 94, pp. 2333-2343, (2002)
  • [8] Malandrino P., Al Ghuzlan A., Castaing M., Young J., Caillou B., Travagli J.P., Elias D., de Baere T., Dromain C., Paci A., Chanson P., Schlumberger M., Leboulleux S., Baudin E., Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma, Endocr Relat Cancer, 17, pp. 797-807, (2010)
  • [9] Fareau G.G., Lopez A., Stava C., Vassilopoulou-Sellin R., Systemic chemotherapy for adrenocortical carcinoma: comparative responses to conventional first-line therapies, Anticancer Drugs, 19, pp. 637-644, (2008)
  • [10] Khan T.S., Imam H., Juhlin C., Skogseid B., Grondal S., Tibblin S., Wilander E., Oberg K., Eriksson B., Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use, Ann Oncol, 11, pp. 1281-1287, (2000)
123456